Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.44 USD | +5.97% | +0.91% | -19.27% |
Mar. 27 | North American Morning Briefing : Stocks Edge -2- | DJ |
Mar. 25 | Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2022 | 9.01M | Sales 2023 | 3.31M | Capitalization | 48.89M |
---|---|---|---|---|---|
Net income 2022 | -29M | Net income 2023 | -8M | EV / Sales 2022 | 2.06 x |
Net cash position 2022 | 4.17M | Net cash position 2023 | 15.11M | EV / Sales 2023 | 10.2 x |
P/E ratio 2022 |
-0.74
x | P/E ratio 2023 |
-5.88
x | Employees | 8 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.83% |
Latest transcript on Marker Therapeutics, Inc.
1 day | +5.37% | ||
1 week | +0.91% | ||
Current month | +3.26% | ||
1 month | -8.26% | ||
3 months | +1.83% | ||
6 months | +52.32% | ||
Current year | -19.27% |
Managers | Title | Age | Since |
---|---|---|---|
Juan F. Vera
CEO | Chief Executive Officer | 44 | 18-10-16 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 18-10-16 | |
Steven Elms
BRD | Director/Board Member | 60 | 19-08-05 |
Katharine Knobil
BRD | Director/Board Member | 60 | 21-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 4.44 | +5.97% | 7 055 |
24-04-22 | 4.19 | +1.21% | 14,370 |
24-04-19 | 4.14 | +0.97% | 14,963 |
24-04-18 | 4.1 | -4.87% | 13,170 |
24-04-17 | 4.31 | -2.05% | 10,686 |
Delayed Quote Nasdaq, April 23, 2024 at 02:19 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-19.27% | 37.3M | |
+3.44% | 42.11B | |
+48.83% | 40.08B | |
+8.68% | 40B | |
-10.82% | 26.87B | |
+8.40% | 24.58B | |
-23.20% | 18.44B | |
+1.70% | 11.94B | |
+34.19% | 11.66B | |
+7.71% | 11.01B |
- Stock Market
- Equities
- MRKR Stock